GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
SEATTLE, Nov. 15, 2016 -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that two abstracts on the Company’s lead product candidate tucatinib (also known as ONT-380) will be presented at the 2016 San Antonio Breast Cancer Symposium (SABCS) to be held December 6-10 in San Antonio, TX.
The Phase 1b “Triplet” poster presentation will include more mature progression-free survival (PFS) and safety data not included in the abstract posted on the SABCS website, which was as of May 2016.
Details of Poster Presentations:
A Phase 2 Randomized, Double-Blinded, Controlled Study of ONT-380 vs. Placebo in Combination with Capecitabine (C) and Trastuzumab (T) in Patients with Pretreated HER2+ Unresectable Locally Advanced or Metastatic Breast Carcinoma (MBC) (HER2CLIMB)
First Author: Erika Hamilton, Sarah Cannon Research Institute, Nashville, TN
Poster/Session: OT1-02-09, Ongoing Trials – Chemotherapy
Date/Time: Wednesday, December 7, 2016; 5:00 p.m.–7:00 p.m. CST
Efficacy Results of a Phase 1b Study of ONT-380, an Oral HER2-Specific Inhibitor, in Combination with Capecitabine (C) and Trastuzumab (T) in HER2+ Metastatic Breast Cancer (MBC), Including Patients (pts) with Brain Metastases (mets)
First Author: Erika Hamilton, Sarah Cannon Research Institute, Nashville, TN
Poster/Session: P4-21-01, Treatment: HER2-Targeted Therapy
Date/Time: Friday, December 9, 2016; 7:30 a.m.–9:00 a.m. CST
About Cascadian Therapeutics
Cascadian Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative product candidates for the treatment of cancer. The lead product candidate, tucatinib, also known as ONT-380, is an oral, selective small molecule HER2 inhibitor. Preliminary results from two ongoing Phase 1b studies of tucatinib in combination showed promising systemic activity, a favorable safety profile and encouraging activity against brain metastases. Cascadian Therapeutics is conducting a randomized, double-blind, placebo-controlled Phase 2 study called HER2CLIMB. The study is evaluating tucatinib versus placebo in combination with capecitabine and trastuzumab in late stage HER2+ breast cancer patients, with and without brain metastases, who have previously been treated with a taxane, trastuzumab, pertuzumab and T-DM1. Additional details can be found at www.clinicaltrials.gov (Identifier: NCT02614794) or www.HER2CLIMB.com. For more information and to sign up for email alerts or RSS feeds, please visit www.cascadianrx.com.
Contacts: Monique Greer Cascadian Therapeutics 206-801-2107 [email protected] Media: Brad Miles BMC Communications 917-570-7340 [email protected]
